Abstract-The effects of s.c. administered salmon calcitonin on the biogenic amine neurotransmitters and metabolites were studied in discrete brain sections in order to evaluate the relationships between these central effects and the fall of serum calcium and to investigate the mechanisms of calcitonin-induced behavioral changes.
Abstract-The effects of s.c. administered salmon calcitonin on the biogenic amine neurotransmitters and metabolites were studied in discrete brain sections in order to evaluate the relationships between these central effects and the fall of serum calcium and to investigate the mechanisms of calcitonin-induced behavioral changes.
The biogenic amines and metabolites were simultaneously determined by high-performance liquid chromatography with electrochemical detection in tissue samples obtained from rats treated with 10-80 MRC U/kg of the peptide. Some rats were pretreated with calcium lactate to inhibit the calcitonin-induced hypo calcaemia.
Most of the effects, consisting of signs of serotonergic system activation, have been observed in the hypothalamus, accounting for some behavioral effects of the peripherally administered salmon calcitonin. It was speculated that the acti vation of the brain serotonergic system could result from two indirect and separate mechanisms: the first, which would involve enhanced serotonin synthesis, seemed to be facilitated by calcium availability.
A second possible mechanism, which would involve enhanced serotonin release from the neurons, seemed to be mediated by the fall of calcium levels in the blood.
It is well-known (1, 2) that the peripheral administration of salmon calcitonin (sCT) induces an increase in the brain levels of serotonin (5HT) and its metabolite 5-hy droxyindole-3-acetic acid (5HIAA), which may be explained by activation of the seroton ergic systems.
On the other hand, the serotonergic sys tems play an important role in several func tions of the central nervous system including the release of hormones from the hypophysis, sensitivity to noxious stimuli, as well as the regulation of food intake, body temperature and locomotor activity. 5HT agonists adminis tered to rats induce head-twitch behavior (3, 4) . These facts are consistent with the observations that sCT influences the release of hormones from the hypophysis (5) (6) (7) (8) , in duces anorexia (9) , depresses the amphet amine-induced locomotor activity (10) and potentiates the head-twitch behavior elicited by 5-hydroxytryptophan (11) . Notwithstand ing, the role of the serotonergic system ac tivation in some of these effects should still be clarified. However, s.c. administered sCT does not have any effect on body temperature (R. Gaggi, unpublished observation). In regard to its effects on the noxious stimuli response, a single sCT injection is ineffective, whereas repeated s.c. administrations in the mouse induce hyperalgesia (12) .
In any case, it is likely that all the central effects of peripherally administered sCT are induced by an indirect mechanism. In fact, there are no convincing data suggesting the idea that this peptide passes the blood-brain barrier. Since the centrally active doses of sCT are high enough to produce hypocalcaemia (13) , and neuronal function has been shown (14, 15) to be sensitive to physiological changes in calcium concentration, it is likely that some sCT effects are mediated by the fall of calcium levels in the blood.
In fact, relationships between the hypo calcaemic and anorectic effects of various calcitonins have been demonstrated (13) . Moreover, it has been hypothesized that the effects mediated by hypocalcaemia also in clude changes in the functional state of the serotonergic system by which sCT poten tiates the head twitch response elicited by 5 hydroxytryptophan (11) . In this regard, it is likely that many other neuronal systems, besides the serotonergic system, should be influenced by hypocalcaemia. This may con tribute to the central effects of sCT.
The aim of the present work was to in vestigate the effects of s.c. administered sCT on the biogenic amine neurotransmitters and its metabolites in discrete brain sections and to evaluate the relationships between these effects and the calcium levels in the serum.
Materials and Methods
Animals and general procedure: Male Sprague-Dawley rats (Nossan, Milano, Italy) weighing 250-300 g were used. They were housed under controlled conditions of light (7:00 a.m.-7.00 p.m.), temperature (22±2°C) and humidity (60%) with food and water ad libitum. On the day of the experiment, all the rats were food deprived at 9:00 a.m. while the water was kept ad libitum. All the rats were sacrificed by means of decapitation in the afternoon (4:00 p.m.-6:00 p.m.). A blood sample was collected and the brain of each animal rapidly removed and ice-cooled. The cerebellum and olfactory tubercles were discarded, whereas the hypothalamus, hip pocampus, striatum, brainstem (pons plus medulla oblongata) and cerebral cortex were dissected (16) . Each sample was immediately frozen with pulvered dry ice and kept at -25 °C until the time of analysis . The rem nant cerebral tissue, consisting mostly of the thalamus and midbrain, was also collected and frozen. In the present work, this brain section will henceforth be designated as the "remnant" .
Chemicals: Synthetic salmon calcitonin (sCT) was kindly supplied by Sandoz Farmaceutici S.p.A. (Milano, Italy) as com mercial vials containing 100 MRC U=20,ug of peptide, 2 mg of acetic acid, 2 mg of sodium acetate, 7.5 mg of sodium chloride and dis tilled water to 1 ml volume. Calcium lactate was obtained'from Fluka AG (Buchs, Switzer land). For the analytical procedure, norepi nephrine (NE), 3,4-d 1hydroxyphenyl -acetic acid (DOPAC), homovanillic acid (HVA), dopamine (DA), serotonin (5HT), 5-hydroxy indole-3-acetic acid (5HIAA), 3,4-dihydroxy benzylamine (DHBA) and octyl sulfate sodium salt (OSA) were obtained from Sigma (St. Louis, MO, U.S.A.). Ascorbic acid and triethylamine were from Farmitalia (Milano, Italy) and methanol was from Inalco S.p.A. (Milano, Italy). The other reagents were pro ducts of Merck (Darmstadt, F.R.G.).
Treatments: The rats were treated with sCT, by the subcutaneous route, and calcium lactate, by the intraperitoneal route, dissolved in saline. The control animals received saline alone. Three experiments were performed.
In the first experiment, 20 MRC U/kg of sCT was administered to 5 groups of 4 rats 8, 4, 2, 1 or 0.5 hr before the sacrifice. A con trol group of 4 rats received saline 0.5 hr before the sacrifice.
In the second experiment, 10 groups of 4 rats were treated with saline or sCT 10, 20, 40 and 80 MRC U/kg, 8 or 2 hr before the sacrifice.
For one part of the third experiment, 4 groups of rats were used. The first two groups were treated with saline, while the third and fourth groups received calcium lactate 100 or 200 mg/kg. After 10 min, the first group received saline, while the remaining 3 groups were sCT-treated. All these rats were sacrific ed 2 hr later. In the same day, another 4 groups of rats were treated in the same way, but the calcium lactate dose for the third and the fourth group was 200 mg/kg. Four hours later, the same dose of the calcium salt was again administered to the fourth group; Thus the rats of this group received 400 mg/kg of calcium lactate (2 x 200 mg/kg at a 4 hr interval). All these rats were sacrificed 8 hr after the sCT administration. The dose of sCT was 20 MRC U/kg. The procedure was re peated using 80 MRC U/kg of sCT. All together, 16 groups of 4 rats were used in the third experiment.
Analytical procedures: The determination of the calcium levels in rat serum was per formed with a colorimetric method (Test combination Boehringer Mannheim GmbH, Mannheim, F.R.G.). The determinations of biogenic amines and its metabolites in the brain sections were performed simultaneously by high-performance liquid chromatography (HPLC) with electrochemical detection (17, 18) . The HPLC system consisted of a P 330 pump (Violet, Roma, Italy) linked to a Rheodyne 7125 injector. The column (OD51 C18: 10 ,um, 25 cm x 4 mm i.d.) and the pre column (ODS1-C18: 10 ,um, 5 cm x 4 mm IA.) were also from Violet. The electrochemical detector (Eldec 103; Chromatofield, Chateau neuf-Les Martigues, France) was connected with a TRIO integrator (Trivector Systems Int., Ltd., Sandy, England). The potential of the glassy-carbon electrode versus silver-silver chloride reference electrode was maintained at +0.8 V. The mobile phase consisted of a 840:160 mixture of 0.1 M NaH2PO4 and methanol. The mixture was made 2.6.10-3 M in OSA, 1.0.10-4 M in EDTA and 2.5.10-4 M in triethylamine, and the pH was adjusted to 3.4 with 3 M H 3 P04. The flow rate was 1.5 ml/min.
All H PLC standards were initially dissolved in deionized double-distilled water. Aliquots of the standard mixture were frozen at -80°C. At the time of the analysis, a frozen aliquot was thawed and diluted 10 times with the medium used for the preparation of the tissue samples. This medium consisted of a freshly prepared solution of the following composi tion: 0.2 M HC104, 2.7.10-4 M EDTA and 1.6.10-4 M ascorbic acid. The frozen brain sections were weighed and immediately ultrasound disrupted in 0.5-2.0 ml of the described medium. After centrifugation for 10 min at 11,000 x g, 20 ,cl of the supernatant were injected into the H PLC apparatus. DH BA was used as an internal standard.
Statistical analysis: The obtained data were analyzed by ANOVAs, followed by the two tailed Dunnett's t-test to compare the in dividual groups to the control. As needed, linear correlation ratios between a measured effect and the log of the sCT doses were computed.
Results
First experiment: Effects of the sCT ad ministered at the dose of 20 M RC U/kg during the 8 hr following treatment: As shown (Table 1) , the treatment induced marked hypocalcaemia (F(5,18)=5.85, P<0.01) that reached its maximum in 30 min (t(5,18)= 4.00, P<0.01) and remained substantially unchanged during the whole period of obser vation (after 8 hr: t(5,18)=4.63, P<0.01).
In regard to the levels of NE, DA, HVA and DOPAC (data not shown) in all the examined brain sections, the sCT did not induce signifi cant changes with respect to control. On the other hand the levels of all these amines and metabolites in the brain sections of the control rats were in the normal range. and in the striatum, the detection of NE was uncertain, but the levels of DA, DOPAC and HVA were, respectively, 9.69±0.31, 1.37±0.027 and 0.63±0.014 ug/g of wet weight.
The 5HT levels (Table 2) were increased 8 hr after the treatment (t(5,18=4.05, P< 0.01) in the hypothalamus alone (F(5,18)= 4.87, P<0.01).
The 5HIAA levels ( hr after the sCT administration, whereas the increases in the 5HIAA levels in the hippocampus (t(5,18)=3.72, P<0.01) and in the remnant (t(5,18)=3.83, P<0.01) were observed only after 8 hr. In the striatum, the levels of HVA, 5HT and 5HIAA were con stantly higher in the treated rats than in the control. However, no significant changes were observed.
The 5HT and 5HIAA levels in the brainstem have shown a similar trend, al though to a lesser extent.
Second experiment: Effects of various doses of sCT administered 8 or 2 hr before the sacrifice: As shown ( Fig. 1) , all the experi mental doses produced marked hypo calcaemia (F(9,30)=12.92, P<0.01 ). In particular, 2 hr after the sCT administration, the effect of 10 Pv1RC U/kg (t(9,30)=6.73, P<0.01) was almost similar to those of 20, 40 (t(9,30)=6.73, P<0.01) and 80 (t(9,30)= 6.41, P<0.01) MRC U/kg of the peptide. The linear correlation between the hypocalcaemic effect and the logarithm of the sCT dose was not significant. In contrast, there was a linear correlation (r=0.812; P<0.01) when the levels of serum calcium were evaluated 8 hr after the treatment. In this case, the group treated at the dose of 10 MRC U/kg was not significantly different from the control, whereas the doses of 20 (t(9,30)=3.63, P< 0.01), 40 (t(9,30)=4.70, P<0.01) and 80 (t(9,30)=6.84, P<0.01) MRC U,/kg of sCT induced significant changes.
In regard to the various brain sections, the treatment did not produce significant changes in the NE, DA, HVA and DOPAC levels (data not shown). The 5HT levels in the hypo thalamus ( Fig. 2) were increased (F(9,30)= 2.94, P<0.05) in animals sacrificed 8 hr after the treatment. The doses of 20 (t(9,30)= 2.82, P<0.06), 40 (t(9,30)=2.86, P<0.05) and 80 (t(9,30)=2.91, P<0.05) MRC U/kg of sCT induced significant changes with respect to the control. However, the linear correlation between the logarithm of the sCT dose and the hypothalamic levels of 5HT was not significant. Two hours after the treatment, the 5HT levels in the hypothalamus were unchanged. The hypothalamic concentra tions of 5HIAA were significantly changed (F(9,30)=4.81, P<0.01) by the treatments. In the rats sacrificed after 8 hr, the linear log dose -.effect correlation was highly significant (r=0.663, P<0.01) because the doses of 20 (t(9,30)=2.54, P<0. P<0.05) and 80 (t(9,30)=3.66, P<0.01) MRC U/kg of sCT produced similar increases in the 5HIAA levels. Therefore, the linear log dose : effect correlation was not significant.
In the hippocampus, the 5HIAA levels alone (Fig. 3A) were significantly changed (F(9,30)=4.89, P<0.01). A.significant coef ficent of linear log-dose : effect correlation (r=0.767, P<0.01) was computed for data obtained from animals sacrificed 8 hr after the treatment. In particular, 80 MRC U/kg of sCT significantly increased the 5HIAA levels (t(9,30)=4.07, P<0.01). No significant differences from the control were observed 2 hr after the treatment.
Almost similar effects were observed in the striatum (Fig. 3B) . The 5HIAA levels in creased (F(9,30)=6.80, P<0.01) in the 8 hr treated rats, showing a linear correlation with the logarithm of the sCT dose (r=0.695, P< 0.01). The highest dose of the peptide induced a significant change with respect to the control (t(9,30)=5.92, P<0.01).
Changes in the 5HIAA levels alone (F(9,30)=12.56, P<0.01) have also been ob served in the remnant of 8 hr treated rats (Fig.  3C) . A marked increase was produced when the sCT dose was 20 (t(9,30) =5.22, P<0.01), 40 (t(9,30)=5.58, P<0.01) or 80 (t(9,30)= 7.68, P<0.01) MAC U/kg. The coefficient of linear log-dose : effect correlation was highly significant (r=0.786, P<0.01).
Third experiment: Inhibition of the sCT induced effects by calcium administration: As shown in Fig. 4A , marked changes in the serum calcium levels were induced in the various groups of rats treated with 20 MAC U/kg of sCT (F(7,24)=18.99, P<0.01). In particular, 2 hr after the peptide administra tion, marked hypocalcaemia was observed (t(7,24)=7.37, P<0.01). This effect was reduced by 100 mg/kg of calcium lactate (t(7,24)=3.74, P<0.01) and abolished by 200 mg/kg of this salt. Equally, 8 hr after the peptide treatment, 200 mg/kg of calcium lactate, administered once every 4 hr, abolish ed the sCT induced hypocalcaemia (t(7,24)= 7.37, P<0.01). A single administration of 200 mg/kg of the calcium salt did not (t(7,24)=5.28, P<0.01). In the hypothalamus (Fig. 5 ) and in the remnant (Fig. 6 ) of these animals the biogenic amines and their me tabolites were determined.
As regards the hypothalamus, the 5HT (F(7,24)=3.88, P<0.01), 5HIAA (F(7,24)= 5.81, P<0.01) and DA (F(7,24)=3.22, P< 0.05) levels were significantly affected. The DOPAC and NE (data not shown) levels remained unchanged with respect to the control. Two hours after the treatment, the sCT administered after 100 (t(7,24)=2.79, P<0.05) or 200 (t(7,24)=3.83, P<0.01) mg/kg of calcium lactate increased the 5HT levels, while the sCT alone did not. On the contrary, 8 hr after its administration, the sCT increased levels of 5HT (t(7,24)=2.82, P< 0.05) were lacking in rats pretreated with the calcium salt. The 5HIAA levels in the hypotha lamus were significantly affected (F(7,24)= 5.81, P-<0.01) by the various treatments. The more important effects consisted of a marked increase in 5HIAA both 2 (t(7,24)= 3.07, P<0.05) and 8 (t(7,24)=4.70, P< 0.01) hr after the administration of sCT alone. In the first case, the increased levels were inhibited by both 100 and 200 mg/kg of calcium lactate. In the latter case, the sCT ) or a high (M) dose. In the rats sacrificed after 2 hr: lo~v dose=100 mg/kg, high dose=200 mg/ka. In the rats sacrificed after 8 hr: low dose=200 mg/kg, high dose=400 mg/kg (2x200 at a 4 hr interval). Results represent the mean of 4 rats+S.E.M. Statistically significant differ ence from the control by the two-tailed Dunnett's t-test (*P<0.01 ). dose. In the rats sacrificed after 2 hr: low dose=100 mg/kg, high dose=200 mg/kg. In the rats sacrificed after 8 hr: low dose=200 mg/kg, high dose=400 mg/kg (2x200 at a 4 hr interval) of the calcium salt. Results represent the mean of 4 rats ±S.E.M. Statistically significant difference from the control by the two-tailed Dunnett's t-test ('P<0.05, **P<0 .01 ). effect was reduced by 200 mg/kg (t(7,24) 3.47, P<0.05) and abolished by 400 mg/l, of the calcium salt. As regards to DA, increase in the hypothalamic content w~ observed in rats treated with 200 mg/kg , calcium lactate and sCT at 2 hr before the were sacrificed (t(7,24)=3.33, P<0.05). In the remnant, NE (F(7,24)=3.92 P< 0.01) and 5HIAA (F(7,24)=6.28, P<0.01) levels were significantly affected, whereas the DA, DOPAC and 5HT concentrations were unchanged. In regard to the NE levels, signifi cant changes were observed only in rats that were sacrificed 8 hr after the sCT injection. The peptide administration reduced the NE levels (t(7,24)=3.07, P<0.05). Calcium lactate abolished this sCT effect at the dose of 400 mg/kg, whereas at the dose of 200 mg/kg, the sCT effect remained unchanged (t(7,24) = 3.51, P<0.01). The 5HIAA levels were increased in rats that had been treated 8 hr before the sacrifice with sCT alone (F(7,24)= 4.57, P<0.01). This effect was reduced by the low dose (t(7,24) =3.24, P<0.05) and abolished by the high dose of calcium lactate.
Calcium levels in the serum (Fig. 4B) were markedly affected when the rats were treated with 80 MRC U/kg of sCT (F(7,24)=19.11, P<0.01). The animals that were treated with peptide alone showed marked hypocalcaemia both 2 hr (t(7,24)=6.25, P<0.01) and 8 hr (t(7,24)=7.83, P<0.01) after treatment. The effect that appeared after 2 hr was reduced (t(7,24)=4.09, P<0.01) and, respectively, abolished by 100 and 200 mg/kg of calcium lactate, In the same way, 400 mg/kg of calcium lactate abolished the effect that ap peared after 8 hr, but 200 mg/kg of this salt did not (t(7,24)=6.37, P<0.01). The rats of these groups were used to determine the biogenic amines and their metabolites in the hippocampus and in the striatum.
In the hippocampus, the 5HIAA levels alone were significantly affected (F(7,24)= 6.43, P<0.01) by the various treatments (Fig.  7) . In particular, these levels were increased 8 hr after the treatment in rats which received sCT alone (t(7,24)=4.98, P<0.01). The high dose of calcium lactate abolished this effect, but the low dose did not (t(7,24)= 3.73, P<0.01).
In the striatum, the 5HIAA (F(7,24)= 11.07, P<0.01) and DOPAC (F(7,24)=2.58, P<0.05) levels were significantly affected (Fig. 8) , but the 5HT, DA and HVA levels were unchanged. The 5HIAA levels were increased 8 hr after the treatment in rats that received Fig. 7 . Levels of 5HIAA in the hippocampus 2 or 8 hr after the s.c. administration cf saline (0) or Fig. 8 . Levels of DOPAC and 5HIAA in the striatum of the same rats in Fig. 7 . For all the other details, see sCT alone (t(7,24)=5.70, P<0.01). The dose of 400 mg/kg of calcium lactate completely inhibited this effect, but the dose of 200 mg/ kg did not (t(7,24)=3.69, P<0.01). Finally, an increase of the DOPAC levels in the striatum was observed in the rats that received sCT and calcium lactate at the dose of 100 mg/kg (t(7,24)=3.68, P<0.01) 2 hr before the sacrifice. The DOPAC levels were unchanged when the peptide alone was administered.
Discussion
As expected, the sCT administered at the dose of 20 M RC U/kg rapidly produced a marked and long-lasting hypocalcaemia. In various brain sections, the 5HIAA content began to increase shortly after the sCT ad ministration;
and in the hypothalamus of treated rats, it became significantly greater than the control in 2 hr. Six hours later, the 5HIAA levels were significantly increased in the hippocampus and remnant also. The in crease in 5HT levels was observed 8 hr after the sCT administration in the hypothalamus alone. These changes could not be attributed to the diurnal variations of 5HT and 5HIAA levels because all the rats were sacrificed at the same time of day (4:00 p.m.-6:00 p.m.). No other significant change in the brain sections was found in the first experi ment, although in the striatum of the sCT treated rats, the 5HT and 5HIAA levels were constantly higher than in their respective control. Therefore, the striatum was also ex amined in the second and third experiments.
The second experiment was undertaken in order to verify if the supra-referred sCT effects were dose-related.
The hypocalcaemic effect that was exhibited 8 hr after the treatment, unlike that exhibited after 2 hr, was linearly related to the logarithm of the sCT dose. This finding can be explained by assuming that all the supraphysiological sCT doses adminis tered to the rats have produced within 2 hr the maximum effect on calcaemia. Therefore, the fall in calcaemia was not dose-related because all the experimental doses have pro duced similar effects. Nevertheless, when the sCT doses were increased from 10 to 80 M RC U/kg, the length of the hypocalcaemic effect appeared proportionately increased. So after 8 hr, the hypocalcaemia was lacking in the rats treated with the low dose, whereas it was still marked in the rats that had received the high dose of the peptide. Therefore, 8 hr after the treatment, the fall in calcaemia could be dose-related.
I n the same way, the 5HIAA levels in the hypothalamus were increased both 2 and 8 hr after the sCT injection: the effect exhibited after 8 hr, unlike that ex hibited after 2 hr, was linearly related to the log-dose of sCT. Similar effects have been found in the hippocampus, striatum and remnant. The 5HIAA levels linearly increased 8 hr after the treatment, but remained un changed after 2 hr. Therefore, it has been as sumed that the increase in 5HIAA levels in the discrete brain sections was related to the size and the lenght of the sCT induced hypocal caemia and that the hypothalamus is more sensitive that the other brain sections to the fall in calcaemia. In particular, a period of 2 hr appeared sufficient to produce the effect in the hypothalamus, but approx. 8 hr each were required for the hippocampus, striatum and remnant. The delay of the cerebral effects with respect to the onset of the hypocalcaemia could be bound to the time required for the rearrangement of the calcium levels in the ex tracellular fluid and in the tissues of the brain. This hypothesis was consistent with the finding that the administration of calcium in hibited both the sCT induced hypocalcaemia and the increase in 5HIAA levels in all the tested brain sections.
As regards to the 5HT, some workers (1) have indicated that the content of this amine in the whole rat brain greatly increased shortly after s.c. administration of sCT. This effect appeared unrelated to the peptide induced hypocalcaemia as well as both the contemporaneous increase of free tryptophan and the decrease of other large neutral amino acids in the serum. It seems likely that these changes in the serum levels of amino acids could greatly enhance the brain synthesis of 5HT, since (a) the free tryptophan competes with the other large neutral amino acids in the transport system across the blood-brain barrier (19) and (b) the tryptophan hydroxylase is not normally saturated with its substrate, tryptophan.
Nevertheless, in the first experi ment, we have observed a significant en hancement of 5HT levels only 8 hr after the sCT administration and in the hypothalamus alone. The disagreement with the previous observations (1) could be attributed, at least partly, to differences in the animals (e.g., body weight: 250-300 g instead of 100 g; cal caemia: 8.95±0.38 instead of 9.9±0.2 mg% ml), in the experimental procedure (fasted rats for 8 instead of 16 hr) and/or in the methods of analysis (separation by HPLC and electrochemical detection instead of separa tion by extraction and fluorimetric determi nation). On the other hand, a moderate in crease in the 5HT synthesis could be masked by an increased release and metabolism of the amine. In fact, the ratio between 5HIAA and the 5HT levels in the various brain sections of treated rats was almost higher than those of the controls. Therefore, the increase in the 5HIAA levels could account for failure of enhanced 5HT levels in some brain sections. For the same reasons, it seems unlikely that an enhanced 5HT synthesis could account for the increased 5HIAA levels. However, in the second experiment, the increase in 5HT levels in the hypothalamus, unlike the hypocalcae mic effect, was not linearly related to the log dose of sCT and, therefore, could not be thought of as being mediated by the fall of the calcium levels in the blood. On the contrary, the data of the third experiment have sug gested that the sCT effect on the 5HT syn thesis was facilitated by the inhibition of the hypocalcaemia. In particular, 2 hr after the sCT administration, the enhancement of the hypothalamic levels of 5HT was greater in the rats treated with calcium lactate than in those treated with saline. Since the 5HIAA remained simultaneously unchanged, an increase in the synthesis, unlike an inhibition of the release and metabolism, should account for the enhanced amine levels. Nevertheless, 8 hr after the treatment with sCT, the hypothala mic 5HT content was enhanced in rats treated with saline, whereas it was unchanged with respect to the control in rats that had received calcium lactate. Therefore, it seemed that in these animals, the 5HT synthesis has been inhibited by the calcium administration. However, considering that the great enhance ment of the 5HT synthesis during the early hours after the sCT and calcium administra tion should have consumed most of the tryptophan, we have assumed that after 8 hr, the hypothalamic 5HT content has been limited by a lowered precursor availability.
Therefore, these present findings agreed with the previous observation (1) that the sCT induced increase in the synthesis of cerebral 5HT is unrelated to hypocalcaemia and, moreover, suggested that this effect is facilitated by calcium.
In conclusion, we assumed that the s.c. ad ministration of sCT activated the serotonergic system by two indirect and separate mech anisms. The first, likely involving changes in the blood levels of large neutral amino acids, appears to be facilitated by calcium adminis tration and enhances the synthesis of neuro transmitter. The latter, likely involving the fall of the calcium levels in the blood that balances the brain extracellular fluid, enhances the release (15) and, consequently, the me tabolism of the neurotransmitter.
The hypo thalamus appeared to be the more sensitive brain section to the actions of sCT. Higher doses of the peptide and/or longer periods of hypocalcaemia were required to produce signs of activation of the serotonergic system in the other brain sections. These signs con sisted of an increase of metabolite levels, while neurotransmitter levels increased to a lesser extent or remained unchanged. How ever, the 5HIAA/5HT ratio was generally in creased with respect to the control. The present findings do not allow us to explain the increase of DA levels in the hypothalamus, the increase of DOPAC levels in the striatum and the decrease of NE levels in the thalamus midbrain induced in rats pretreated with the calcium salt. Nevertheless, on the whole, these findings have suggested that the sCT effects on the rat central nervous system could be greatly influenced by changes in calcium availability.
Finally, the data obtained on the changes in the levels of monoamine neurotransmitters and metabolites in rat brain could account for some of the sCT induced behavioral effects, principally those that involve more directly the serotonergic systems as the anorectic effect (20) , the inhibition of amphetamine induced hypermotility (21) and the head twitch response (11) .
